薬剤排出ステントの比較のために,ルメン直径の遅い損失とバイナリレステノシス
Laura Mauri1, E John Orav, Richard E Kuntz
1Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02116, USA. lmauri1@partners.org
Circulation
|June 22, 2005
まとめ
ルーメン直径の遅い損失は,冠動脈ステントのレステノシスリスクの信頼できる予測指標です. この血管学的測定は,特に新しい薬剤排出ステントでは,従来のレステノス比率よりも高い統計的力を提供します.
科学分野:
- 心血管研究 循環器科の研究
- 介入性心臓病学 介入性心臓病学
- バイオメディカルエンジニアリング
背景:
- 冠動脈回復率は,薬剤排出ステントによって著しく低下しています.
- 早期のステント評価では,しばしば代理連続エンドポイントを使用します.
- これらの代替エンドポイントの汎用性と力は,体系的な調査を必要とします.
研究 の 目的:
- 遅いルメンの喪失とレステノシスの確率の間の関係を評価する.
- 後期ルメン損失とバイナリレステノシスの統計的力を比較する.
- 新しいステント試験のエンドポイントとして,遅いルメン損失を評価する.
主な方法:
- 公開された22件のステント試験からの遅いルメン損失データの分析.
- 裸金属,薬物放出,および小血管ステントを含む.
- 遅い損失の差とバイナリレステノシス率の間のパワー比較.
主要な成果:
- ステントのタイプや血管の直径に関係なく,平均遅い損失と標準偏差の間の線形関係が観察されました.
- 遅いルメンの損失の増加は,単調にレステノシスリスクの上昇と関連していました.
- 遅いルメン損失は,バイナリレステノシスと比較して,治療効果を検出する能力が著しく高いことを示しました.
結論:
- 遅いルメン損失は,一般化可能で強力な血管学的エンドポイントです.
- それは,様々なステントタイプにおけるレステノシスリスクと強く,単調に関連しています.
- 遅いルメン損失は,新しい薬剤排出ステントの初期試験に特に価値があります.
関連する概念動画
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...


